Six Pharma Stocks Offer Up To 28% Upside Despite Macro Headwinds In 2026

Pharma Sector Outlook

India’s pharmaceutical industry is valued at USD 55 billion in 2026 and is projected to reach USD 130 billion by 2030. Growth is supported by 12–14% domestic branded formulation expansion, recovery in the US generics market, and increasing focus on specialty molecules and biologics.

Six Pharma Stocks With Upside Potential

Sun Pharmaceutical Industries

India’s largest pharma company with leadership in dermatology and branded generics across 100+ countries. Analysts highlight its specialty portfolio (Ilumya, Winlevi, Levulan) with USD 2 billion revenue potential by FY28. Upside: ~20%.

Dr. Reddy’s Laboratories

Fastest-growing large-cap pharma with 15% revenue growth. Strong biosimilars pipeline and US generics recovery position it for up to 25% upside.

Cipla Ltd

Respiratory therapies and branded generics specialist. Domestic demand and device innovation support ~18% upside.

Torrent Pharmaceuticals

Diversified presence across India, US, and Europe. Chronic care portfolio in diabetes and cardiology drives ~22% upside.

Divi’s Laboratories

Premium API manufacturer with strong export base. Quarterly profit growth of 35% YoY and ROCE of 20.44% make it attractive, with up to 28% upside.

Zydus Lifesciences

Strong pipeline in vaccines and biologics. Analysts expect 15–20% upside, supported by specialty launches and domestic growth.

 Investor Insights

• Sun Pharma leads with specialty drug expansion
• Dr. Reddy’s benefits from US generics recovery
• Cipla strengthens respiratory and branded generics portfolio
• Torrent Pharma focuses on chronic care therapies
• Divi’s Labs shines with API exports and premium valuation
• Zydus Lifesciences builds pipeline in vaccines and biologics

Sources: Univest, Motilal Oswal, Moneycontrol, Tickertape